gemcitabine has been researched along with Genetic Predisposition in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Arentsen-Peters, STCJM; Castro, PG; Cheung, LC; Chua, GA; Dolman, MEM; Jones, L; Kerstjens, M; Koopmans, B; Kotecha, RS; Molenaar, JJ; Pieters, R; Pinhanҫos, SS; Schneider, P; Singh, S; Stam, RW; Wander, P; Zwaan, CM | 1 |
| Che, X; Cheng, X; Du, Z; Huang, X; Li, J; Lin, D; Shao, M; Tan, W; Wang, C; Wu, C; Zhao, Y; Zheng, J | 1 |
| Bamlet, WR; Bentrem, DJ; Etheridge, AS; Glubb, D; Gordân, R; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, H; McWilliams, RR; Mulkey, F; Nakamura, Y; Neel, N; Niedzwiecki, D; Owzar, K; Petersen, GM; Ratain, MJ; Seiser, E; Sibley, AB; Talamonti, MS; Van Loon, K; Venook, AP; Yeh, JJ | 1 |
| Jiménez Gordo, AM; López Gómez, M | 1 |
| Hong, D; Hong, W; Kou, JY; Mao, WM; Su, D; Wang, K; Wang, XJ; Xie, FJ; Yu, XM; Zhang, YP | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Cheung, DY; Jeong, M; Kang, CS; Kim, HS; Kim, IK; Kim, JI; Kim, TJ; Seo, JH | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Hasegawa, R; Kamatani, N; Kaniwa, N; Kawamoto, M; Kim, SR; Kim, WY; Lee, SJ; Lee, SS; Okuda, H; Saito, Y; Sawada, J; Shin, JG; Sugiyama, E; Tohkin, M | 1 |
3 review(s) available for gemcitabine and Genetic Predisposition
| Article | Year |
|---|---|
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Diabetes Mellitus; Diet; Drug Resistance, Neoplasm; Early Detection of Cancer; Fluorouracil; Gemcitabine; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Radiosurgery; Risk Factors; Spain | 2019 |
Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; CA-19-9 Antigen; Cell Differentiation; Deoxycytidine; DNA Mutational Analysis; Exons; Gemcitabine; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Pancreatic Neoplasms; Phenotype; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sarcoma; Tomography, X-Ray Computed; Up-Regulation | 2014 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
2 trial(s) available for gemcitabine and Genetic Predisposition
| Article | Year |
|---|---|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Cell Line, Tumor; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Receptors, Calcitriol; RNA, Messenger; Vitamin D | 2018 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
4 other study(ies) available for gemcitabine and Genetic Predisposition
| Article | Year |
|---|---|
Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Management; Disease Models, Animal; Drug Evaluation, Preclinical; Gemcitabine; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Infant; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2020 |
Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Genetic Predisposition to Disease; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Survival Analysis; Treatment Outcome | 2018 |
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Prevalence; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2013 |
Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
Topics: Alleles; Antimetabolites, Antineoplastic; Antirheumatic Agents; Asian People; Black or African American; Black People; Cytarabine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; White People | 2009 |